Michael Rabinowitz's most recent trade in Oramed Pharmaceuticals, Inc was a trade of 11,900 Common Stock done at an average price of $12.5 . Disclosure was reported to the exchange on Jan. 3, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc | Michael Rabinowitz | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 12.49 per share. | 03 Jan 2023 | 11,900 | 126,143 (0%) | 0% | 12.5 | 148,651 | Common Stock |
| Oramed Pharmaceuticals Inc | Michael Rabinowitz | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 13.01 per share. | 03 Jan 2023 | 1,425 | 138,043 (0%) | 0% | 13.0 | 18,544 | Common Stock |
| Oramed Pharmaceuticals Inc | Michael Rabinowitz | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 30,000 | 139,468 (0%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals Inc | Michael Rabinowitz | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | |
| Oramed Pharmaceuticals Inc | Michael Rabinowitz | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 19,000 | 109,468 (0%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals Inc | Michael Rabinowitz | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.98 per share. | 28 Dec 2021 | 9,532 | 90,468 (0%) | 0% | 13.0 | 123,725 | Common Stock |
| Oramed Pharmaceuticals Inc | Michael Rabinowitz | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2021 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Oramed Pharmaceuticals Inc | Michael Rabinowitz | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) |